Taeyeon Jeon of Alteogen
Stresses the Importance of Patent Acquisition and Technology Commercialization

Taeyeon Jeon, CEO of Alteogen, is giving a presentation titled "Global Bio Licensing Strategy" at the "2026 Public Technology Commercialization Conference (PTC Korea)" jointly hosted by the National Science and Technology Research Council (NST) and the Korea Association of Research Industry Technology Transfer (KARIT) held in Gyeongju on the 26th. Photo by Paek Jongmin, Tech Specialist

Taeyeon Jeon, CEO of Alteogen, is giving a presentation titled "Global Bio Licensing Strategy" at the "2026 Public Technology Commercialization Conference (PTC Korea)" jointly hosted by the National Science and Technology Research Council (NST) and the Korea Association of Research Industry Technology Transfer (KARIT) held in Gyeongju on the 26th. Photo by Paek Jongmin, Tech Specialist

View original image

Taeyeon Jeon, CEO of Alteogen, cited "patents" as the key factor behind enabling global technology exports worth approximately 12 trillion won. He explained that combining a business model in which a single platform technology is applied across multiple pharmaceuticals with long-term patent protection led to large-scale contracts with global pharmaceutical companies.


CEO Jeon gave a presentation titled "Global Bio Licensing Strategy" at the "2026 Public Technology Commercialization Conference (PTC Korea)" jointly hosted by the National Science and Technology Research Council (NST) and the Korea Association of Research Industry Technology Transfer (KARIT) in Gyeongju on the 26th.


What CEO Jeon emphasized was the power of intellectual property (IP) that ensures such technology can be exclusively utilized, rather than the technology itself. He stressed, "No matter how excellent the technology is, unless a global pharmaceutical company can exercise exclusivity, it cannot command its full value."


He said, "Since 2019, we have signed contracts with nine global pharmaceutical companies for a single Hybrozyme technology," adding, "Taking exchange rates into account, the amount is approximately 12 trillion to 13 trillion won."


The protection period for the U.S. substance patent related to ALT-B4 lasts until 2043. During the COVID-19 pandemic, the patent period was extended due to Patent Term Adjustment (PTA) resulting from examination delays at the United States Patent and Trademark Office. Alteogen's partner companies mainly apply ALT-B4 to blockbuster pharmaceuticals.


CEO Jeon holds a Ph.D. in biochemistry and is a registered U.S. patent attorney, making him an expert in patents. He stressed that when negotiating technology exports with global pharmaceutical firms, it is essential from the early stages of research and development to design patents alongside business strategies, as the scope of patent rights, inventorship, and potential conflicts with competitor patents are all scrutinized—not just technical performance.



CEO Jeon also highlighted the importance of commercialization after contract signing. He explained, "Once a contract is signed, many very difficult challenges arise," emphasizing that continuous collaboration with partners on clinical trials, regulatory approval, and commercialization is necessary to ensure these agreements translate into tangible business outcomes.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing